Cargando…
Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding specificity to CD20. It was the first therapeutic antibody approved for oncology patients and was the top-selling oncology drug for nearly a decade with sales reaching $8.58 billion in 2016. Since its initial approval...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994406/ https://www.ncbi.nlm.nih.gov/pubmed/29915719 http://dx.doi.org/10.3389/fonc.2018.00163 |